Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Latanoprost
Drug ID BADD_D01251
Description Latanoprost is a prodrug analog of prostaglandin F2 alpha that is used to treat elevated intraocular pressure (IOP). It was initially approved by the FDA in 1998. Latanoprost is the first topical prostaglandin F2 alpha analog used for glaucoma treatment.[A184493] It has been found to be well-tolerated and its use does not normally result in systemic adverse effects like other drugs used to treat elevated intraocular pressure, such as [Timolol]. Another benefit latanoprost is that it can be administered once a day.[A184490]
Indications and Usage Latanoprost is indicated for the reduction of elevated intraocular pressure in patients who have been diagnosed with open-angle glaucoma or ocular hypertension.[L8357] Latanoprost may be combined in a product with [Netarsudil], a rho kinase inhibitor, for the same indications.[L8369] In addition to the above indications, the Canadian monograph for this drug also approves latanoprost for the treatment of elevated intraocular pressure as a result of angle-closure glaucoma that has been treated with peripheral iridotomy or laser iridoplasty.[L8366]
Marketing Status approved; investigational
ATC Code S01EE01
DrugBank ID DB00654
KEGG ID D00356
MeSH ID D000077338
PubChem ID 5311221
TTD Drug ID D0C6NM
NDC Product Code 65727-026; 82187-1002; 71205-154; 62991-3186; 65427-007; 82231-111; 50090-1920; 59762-0333; 54893-0010; 63190-0710; 65326-004; 61314-547; 65862-872; 0009-5172; 12079-0475; 42385-039; 51552-1385; 51927-4864; 68245-0002; 81997-001; 10695-048; 90027-006; 47335-317; 70069-421; 65035-128; 71684-0547; 73212-027; 55545-0462; 71052-041; 24208-463; 64980-516; 68071-4612; 40016-001; 61556-050; 0013-8303; 24002-0018; 73377-237
UNII 6Z5B6HVF6O
Synonyms Latanoprost | PhXA34 | PHXA41 | Xalatan
Chemical Information
Molecular Formula C26H40O5
CAS Registry Number 130209-82-4
SMILES CC(C)OC(=O)CCCC=CCC1C(CC(C1CCC(CCC2=CC=CC=C2)O)O)O
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice.
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Pregnancy18.08.02.0040.000067%-
Pruritus23.03.12.001--
Punctate keratitis06.04.02.0030.000112%-
Rash23.03.13.001---
Retinal artery embolism06.10.01.006; 24.01.07.004---
Retinal detachment06.09.03.003; 12.01.04.0040.000135%
Retinal oedema06.04.06.007; 24.03.07.0060.000045%-
Retinal vascular disorder06.10.01.002; 24.03.07.0020.000045%
Rhinorrhoea22.12.03.0210.000405%
Scab23.03.03.004---
Sjogren's syndrome06.08.02.011; 07.06.01.010; 10.04.04.009; 15.06.01.0150.000067%-
Skin discolouration23.03.03.0050.000472%-
Skin disorder23.03.03.007---
Skin irritation23.03.04.0090.000198%-
Skin reaction10.01.03.019; 23.03.03.013---
Sneezing22.12.03.0240.000153%
Swelling08.01.03.0150.000526%-
Swelling face08.01.03.100; 10.01.05.018; 23.04.01.0180.000441%-
Syncope02.11.04.015; 17.02.04.008; 24.06.02.0120.000225%
Throat irritation07.05.05.037; 22.12.03.0290.000090%-
Tinnitus04.04.01.002; 17.04.07.0040.000252%
Toxic epidermal necrolysis10.01.01.006; 11.07.01.006; 12.03.01.015; 23.03.01.008--
Upper respiratory tract infection11.01.13.009; 22.07.03.011--
Urinary tract infection11.01.14.004; 20.08.02.001--
Uveitis06.04.03.003; 10.02.01.0230.000144%
Ventricular extrasystoles02.03.04.0070.000099%-
Vertigo04.04.01.003; 17.02.12.0020.000396%
Vision blurred06.02.06.007; 17.17.01.0100.003234%
Visual acuity reduced06.02.10.012; 17.17.01.0110.001251%
Visual field defect06.02.07.003; 17.17.01.0010.000459%-
The 5th Page    First    Pre   5 6 7 8    Next   Last    Total 8 Pages
ADReCS-Target
Drug Name ADR Term Target
Tip:  Drug Name  ADR Term  Protein  Variation  Gene